All Videos

Mona Shahriari, MD, explores potential areas of research that can contribute to continuous improvement in pediatric atopic dermatitis management.

Mona Shahriari, MD, expands on benefits of ruxolitinib in managing itch and inflammation in pediatric atopic dermatitis.

Michael Cameron, MD, identifies comorbidities, lifestyle factors, and educational opportunities AAD guidelines provide insight on for patients with atopic dermatitis.

Michael Cameron, MD, identifies the most important pearls from the latest atopic dermatitis treatment guidelines set forth by the American Academy of Dermatology.

Sonya Kenkare, MD, explains her approach to itch and the support system of multiple specialties to help a pediatric patient with atopic dermatitis.

Sonya Kenkare, MD, details where ruxolitinib fits within the current landscape of pediatric atopic dermatitis treatments.

Lisa Swanson, MD, FAAD, sheds light on the enhanced accessibility of ruxolitinib cream, highlighting its improved availability for patients in need.

Brad Glick, DO, MPH, FAAD, notes the absence of location restrictions with topical ruxolitinib cream, distinguishing it from topical corticosteroids. The panel discusses the cyclic pattern of steroid use and the potential of ruxolitinib cream as a continuous treatment option.

Dermatology experts evaluate topical ruxolitinib cream's effectiveness in rapidly relieving itch and offer guidance on its black box warning. They also discuss its efficacy in children under 2, highlighting its suitability for those with tactile sensitivity.

Dr James Del Rosso underscores the importance of phase 2 and dose-ranging studies to uncover efficacy differences between therapies, while the panel explores how clinical data from ruxolitinib trials mirrors real-world outcomes.

James Del Rosso, DO, Brad Glick, DO, MPH, FAAD, and Lisa Swanson, MD, FAAD, address the demand for non-steroidal treatment alternatives while navigating the individualization of data interpretation regarding these treatments.

Dr. Alexandra Golant shares invaluable practice pearls for optimizing the management of hand and foot atopic dermatitis with the use of systemic treatments.

Dr Alexandra Golant discusses managing multiple conditions in a 17-year-old African American waitress, highlighting the complexities of treating moderate-to-severe atopic dermatitis alongside severe acne and oral contraceptives. She also addresses potential drug interactions, focusing on the safety of dupilumab in systemic treatment.

Dr Golant continues with the case of the 38-year old patient with atopic dermatitis and explore effective strategies for navigating treatment selection and planning in this condition, focusing on discussing options with patients and instilling confidence in the chosen approach.

Alan Irvine, MD, DSc, shares insights on the impact of ruxolitinib on quality of life in pediatric patients and 2024 AAD research presentations to take into consideration.

Dr Linda Stein Gold and Dr Michael Cameron assess the safety and tolerability of topical ruxolitinib cream, offering guidance on counseling patients about the black box warning. They also address the perception of limited treatment access and strategies for overcoming this barrier.

Alan Irvine, MD, DSc, offers an understanding of BSA changes and anti-inflammatory effects of ruxolitinib in the latest research presented.

Ruth Ann Vleugels, MD, MPH, MBA, delves into patient-specific considerations and action plans when on a JAK inhibitor, including shingles prevention and management.

Experts in dermatology review the rapid itch relief provided by topical ruxolitinib cream and attribute its fast-acting efficacy to its mechanism of action targeting a variety of interleukins.

Linda Stein Gold, MD, and Michael Cameron, MD, FAAD, discuss the need for non-steroidal treatment options in atopic dermatitis management, driven by patient preferences. They highlight the challenges with previous oily options, which often caused tolerability and irritation issues, and how the approval of ruxolitinib cream addresses these concerns.

Ruth Ann Vleugels, MD, MPH, MBA, shares insights that she gives her own residents on JAK inhibitor selection, risks, benefits, and data available.

Experts in dermatology share closing thoughts on the management of plaque psoriasis.

Drs Mark Lebwohl and Saakshi Khattri review recent advancements and emerging therapies in development for plaque psoriasis treatment.

David Rosmarin, MD, acknowledges opportunities for further research in diverse populations to continue updating AD treatment guidelines.

David Rosmarin, MD, addresses the research gaps in recommendations for systemic therapies in atopic dermatitis in the latest guidelines.

Mark Lebwohl, MD, discusses the rapid expansion of therapeutic options, including targeted drugs like JAK inhibitors and IL-13 treatments for atopic dermatitis, paralleling the progress seen in psoriasis treatment over the last decade.

Mark Lebwohl, MD, emphasizes the importance of considering various factors, including severity of itch and interference with sleep, when determining treatments for patients with atopic dermatitis, even with presentation may not include typical symptoms.

Alexandra Golant, MD, shares how sleep improvement is measured and the difference an effective treatment makes for the patient’s entire family.

Alexandra Golant, MD, explains why she is confident in the latest safety and efficacy data from ruxolitinib trials to treat pediatric patients with atopic dermatitis.

Alexandra Golant, MD, presents the case of a 38-year-old Caucasian male construction worker, diagnosed with moderate AD at age 15, and his treatment history with various interventions and physician referral considerations.